Latest Conference Articles

According to results from the CORALLEEN trial presented at the San Antonio Breast Cancer Symposium, neoadjuvant treatment with the cyclin-dependent-kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to multi-agent chemotherapy in patients with high-risk luminal B breast cancer.

Banu Arun, MD, explains the various reasons for the lack of genetic testing in appropriate candidates. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Oncolytic Viral Therapy (OVT) is currently not recognized by treatment guidelines for advanced pancreatic cancer; however, safety and efficacy data from previous studies conducted over the previous 10 years have shown that OVT may be a promising, innovative approach for patients with pancreatic cancer.

Abemacilib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for hormone receptor, human epidermal growth factor receptor 2 metastatic breast cancer.

Jaclyn Harth, PharmD, clinical assistant professor, Fairleigh Dickinson School of Pharmacy, discusses the role of the health system pharmacist for patients with chronic hyperkalemia. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

A study evaluated the real-world benefit of palbociclib plus endocrine therapy as a first-line treatment in HR-positive, HER2-negative metastatic breast cancer to correlate the efficacy of the combination with neutropenia.

Patricia Spears discusses the various approaches to discussing clinical trials, and in which situations to use them. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

Pharmacy professionals with the Practice Advancement Initiative (PAI) 2030 have instituted 59 recommendations to promote optimal, safe, and effective medication use, expand pharmacist and technician roles, and implement the latest technologies.

Researchers have confirmed that the addition of the CDK4/6 inhibitor abemaciclib to aromatase inhibitors is associated with durable tumor responses.

The EGFR/RAS/MEK pathway may serve as a predictive biomarker for palbociclib plus fulvestrant resistance and offer therapeutic targets to overcome resistance in patients with ER-positive/HER2-negative breast cancer.

Edina Avdic, PharmD, MBA, BCPS-AQ ID, associate director, Antimicrobial Stewardship Program, The Johns Hopkins Hospital in Baltimore, Maryland, discusses current antiviral treatments for influenza. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

In order to improve the efficacy of checkpoint blockade treatments in patients with breast cancer, it is necessary to consider treatment through the lens of the cancer immunity cycle.

Banu Arun, MD, explains why genetic testing is important and its intended uses for treatment in patients with breast cancer during the 2019 San Antonio Breast Cancer Symposium.

Danny Sanchez, vice president and general manager, Population Health Services for Omnicell, discusses how technology can improve adherence. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas.

The study results were presented at the 2019 San Antonio Breast Cancer Symposium, held December 10 through 14.

Despite the fact that menopausal hormone therapy with estrogen plus progestin is frequently used, its influence on breast cancer incidence and mortality has been debated, with discordant findings from prospective observational studies compared with randomized clinical trials.

Peter Schmid, FRCP, MD, PhD, discusses the 5 most common immune-related side effects seen in breast cancer patients. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Although there is no standard of care therapy following second-line treatment for human epidermal growth receptor 2 (HER2)-positive breast cancer, there are a number of options being researched.

By identifying molecular alterations contributing to CDK4/6i resistance, researchers hope to better understand which patients with breast cancer will respond best to the therapy.

Patients with metastatic breast cancer (MBC) who received an oral formulation of the chemotherapy drug paclitaxel (Taxol) had a better response and survival and elss neuropathy than patients who received intravenous (IV) paclitaxel.

Tim Ulbrich, PharmD, co-founder and CEO of Your Financial Pharmacist, discusses some ways to invest in your career. This video was at the ASHP (American Society of Health-System Pharmacists) Midyear Clinical Meeting & Exhibition in Las Vegas.

Health care facilities are not immune from active shooter incidents, and pharmacists in these workplaces need to know how to respond, according to a session at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada.

With the spike in vaping-related illnesses are at an all-time high, staying on top of the news and counseling patients properly are some ways that pharmacists can help fight the epidemic, according to a session at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas.

Investigators have established a genomic outline of the CDK4/6i resistance in patients with breast cancer, growing the potential for novel treatments to circumvent that resistance.

Cyclin-dependent kinase 4/6 inhibitors offer the potential to significantly improve outcomes for women with HR-positive, HER2-negative breast cancer.

The study results also show improved outcomes for patients with brain metastases.

Megan Maroney, PharmD, BCPP, clinical associate professor, Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey; clinical psychiatric pharmacist, Monmouth Medical Center, Long Branch, NJ, discusses suicidal ideation and behavior, and depression, as potential adverse effects of some medications.

Although CDK4/6 inhibitors prolong progression-free survival for patients with estrogen receptor-positive breast cancer, the ideal treatment for each patient is currently unclear until adverse effects appear.